The causal association of polyunsaturated fatty acids with allergic disease: A two-sample Mendelian randomization study

Yajia Li1,2, Qiangxiang Li2,3,4, Ziqin Cao2,5* and Jianhuang Wu2,5*

1Department of Dermatology, Xiangya Hospital, Central South University, Changsha, China, 2National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China, 3Ningxia Geriatric Disease Clinical Research Center, People’s Hospital of Ningxia Hui Autonomous Region, Yinchuan, China, 4Hunan People’s Hospital, Department of Hunan Institute of Geriatrics, Changsha, China, 5Department of Spine Surgery and Orthopaedics, Xiangya Hospital, Central South University, Changsha, China

Objectives: Previous studies have reported a potential association of polyunsaturated fatty acids (PUFAs) levels with allergic disease risk and the possible benefit of PUFAs supplementation on allergic disease prevention. This study was performed to estimate the genetic association between PUFAs and allergic diseases using the method of both univariable and multivariable two-sample Mendelian randomization (MR).

Methods: As indicators of the PUFAs levels, we included the omega-3, omega-6, docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA), linoleic acid (LA), and the ratio of omega-6 to omega-3 (omega-6:3). Summarized statistics of genome-wide association studies (GWASs) for these PUFAs were obtained from the United Kingdom Biobank and the Twins United Kingdom cohort. Genetic data relating to allergic diseases, including atopic dermatitis (AD), allergic rhinitis (AR), allergic conjunctivitis (AC), allergic urticaria (AU) and asthma, were accessed from the FinnGen biobank analysis. Odds ratios and 95% CIs were used to express the impact.

Results: The MR results denoted a genetic association between the genetically determined increase in omega-3 levels and the decreased risk of some allergic diseases including AD (OR: 0.863; 95% CI: 0.785 to 0.949; \( p = 3.86 \times 10^{-3} \)), AC (OR: 0.720; 95% CI: 0.547 to 0.947; \( p = 1.87 \times 10^{-2} \)) and AU (OR: 0.821; 95% CI: 0.684 to 0.985; \( p = 3.42 \times 10^{-2} \)), while omega-6 and DHA level was only found to have negatively correlation with risk of AC with ORs of 0.655 (95% CI: 0.445 to 0.964; \( p = 3.18 \times 10^{-2} \)) and 0.671 (95% CI 0.490 to 0.918; \( p = 1.25 \times 10^{-2} \)), respectively. Omega-6:3 were causally significantly associated with the increased risk of AD (IVW: OR: 1.341; 95% CI: 1.032 to 1.743; \( p = 2.83 \times 10^{-2} \)) and AC (IVW: OR: 1.341; 95% CI: 1.032 to 1.743; \( p = 2.83 \times 10^{-2} \)). After adjustment of age, economic level, BMI, smoking and alcohol behaviors in the multivariable MR analysis, a direct causal protective effect of omega-3 on AD and AC, as well as a direct causal association between DHA and AD were observed. Omega-6:3
was also found to be directly associated with an increased risk of AD and AC. No association was found of EPA or LA with allergic diseases.

**Conclusion:** Higher PUFA concentrations (omega-3, omega-6, DHA) and lower omega-6:3 ratios were genetically associated with a lower risk of some allergic diseases.

**KEYWORDS**

polyunsaturated fatty acids, omega-3, omega-6, allergic diseases, Mendelian randomization study

**Introduction**

Allergic diseases may involve the respiratory, digestive, skin or other systems and include common conditions such as eczema/atopic dermatitis (AD), allergic asthma, allergic rhinoconjunctivitis (AR/AC)/hay fever/seasonal allergies and allergic urticaria (AU) (1). It is also widely accepted that AD comorbidities extend beyond other allergic conditions, such as AA, AR, AC, and eosinophilic esophagitis, and that allergic diseases follow time-based sequences, suggesting both cutaneous and systemic immune activation (1–3). There has been a noticeable increase in the incidence of allergic disease, which now affects an estimated 20% of the population, making it a public health concern (2, 4, 5). Some allergic conditions with childhood-onset resolve with age, whereas others may persist throughout the lifetime (6), leading to an increased burden on families, society, and healthcare services (7). The rapid escalation of allergic diseases may not be attributed to either genetic or environmental factors (such as lifestyle and diets) alone, and mixed etiology is not fully understood (8). The association between genetic factors and allergic diseases has been extensively studied and some shared susceptibility loci have been identified (9). Large-scale genome-wide association studies (GWAS) and studies of causal roles of genetic susceptibility loci are expected to improve understanding of the prevention and treatment of atopic diseases.

Polyunsaturated fatty acids (PUFAs) of the omega-3 and omega-6 series have been identified by laboratory and epidemiological evidence as having anti-inflammatory and anti-allergy effects (10–13). Especially for omega-3, systematic reviews and meta-analyses have shown the impact of the fish oil-derived omega-3 PUFAs in the primary prevention of allergic disease (14, 15). Indeed, the omega-3 PUFA, docosahexaenoic acid (DHA), and eicosapentaenoic acid (EPA) have been shown to have anti-inflammatory and immunoregulatory properties (13). On the contrast, linoleic acid (LA), one type of omega-6 acid, was found to be linked to increased specific IgE and pro-inflammatory responses among infants (16–18). The ratios of omega-6 to omega-3 PUFAs in some Western diets are found to arise from an equal balance of 1:1 to an unbalanced level of nearly 30:1. The significant changes in PUFAs consumption seem to be paralleled by the increase in the prevalence of atopic and allergic diseases (19), indicating a potential causal relationship between PUFA intake and allergic diseases.

PUFA supplementation has been proposed to prevent allergic disease, and genetic evidence must be considered in establishing the causal effects (20). The current study employed Mendelian randomization (MR) analysis, using instrumental variables (IVs) to explore a causal association of exposure factors with outcomes (21–23). The theory of random distribution of genetic variants within the population, which mimics the randomization process in the assortment of meiosis genetic variants, underpins the approach. An analogy between MR and RCTs may be drawn, with the former less likely to be affected by confounders and reverse causality (24). Two-sample MR analysis relies on genetic effect estimates from two independent summary sets of GWAS to the inference of causal association by comparison with one-sample MR (25). Multivariable MR (MVMR) is an extension of univariable MR and can take the pleiotropy in multiple traits into account. The assumptions of MVMR include the possible effects of genetic variants on multiple measured exposures and the extension of the exclusion restriction and exchangeability assumption (26). Therefore, MVMR can provide a consistent estimator of the direct effect of the primary exposure on the outcome that does not work via the mediator, even when a secondary exposure act as a mediator in the relationship. The current study aimed to infer causal associations between PUFAs (using genetic IVs as proxy) and with risk of atopic disease through a two-sample MR analysis (27).

**Materials and methods**

The overview flowchart of the hypothesis and schematic design is shown in Figure 1. Three principal assumptions were made (Figure 1A) (28): (1) genetic variants were strongly associated with exposure; (2) genetic variants were only
associated with the outcome through exposure, and (3) this association was independent of any potential confounders. Publicly available data were used, and no additional informed consent or ethical approval was required. Genetic data were obtained from two large GWAS and, after removing outliers and harmonizing alleles, MR analysis with six different methods and sensitivity analysis was applied to identify causal associations between PUFAs and allergic diseases.

Data source and selection of genetic instrumental variables

Single-nucleotide polymorphisms (SNPs) were identified and used as IVs from eligible datasets in GWAS Catalog, IEU openGWAS and NealeElab. Only GWAS conducted on individuals of European ancestry were included to limit the bias resulting from ethnic confounders. Six main dietary PUFAs indexes were considered in the present study: SNPs for circulating omega-3, omega-6, DHA, EPA, and LA levels, as well as the ratio of omega-6 to omega-3 fatty acids (omega-6:3), were also obtained as instrumental variables of exposure. Genetic risk variants of exposure including omega-3, omega-6, DHA, LA, and omega-6:3 were identified from the Metabolic biomarkers in the United Kingdom Biobank (Nightingale Health 2020). Circulating omega-3 and omega-6 fatty acids, as well as DHA and LA concentrations, were measured from randomly selected EDTA plasma samples by using a targeted high-throughput nuclear magnetic resonance (NMR) metabolomics platform (Nightingale Health Ltd; biomarker quantification version 2020) (29). In total, 121,577 samples were retained for analyses after removing duplicates and observations not passing quality control in the non-fasting plasma samples collected at baseline, and 114,999 samples were retained in the final. Details for measurement technology and applications for the epidemiology of this platform have been previously reviewed (30–32). For the EPA level, it was obtained from the Twins United Kingdom cohort (33), which is an adult twin British registry composed of mostly women recruited from the general United Kingdom population through national media, and the EPA level was measurable in blood using the Metabolon platform. The detailed information was described in the previous studies (34–36). Genetic data relating to AD, AC, AR, AU, and asthma were accessed from the FinnGen biobank analysis (round 5), and diagnoses were based on ICD-10 (Figure 1B).

Summarized statistics of PUFAs-related SNPs with genome-wide significance ($p < 5 \times 10^{-8}$) were designated as alternate IVs. Linkage disequilibrium (LD) was tested within the condition of the clumping algorithm with $r^2 = 0.001$ and kb = 10,000 to reduce the effect of strong LD. $F$ statistics were used to assess the risk of weak instrumental bias with at least 10 being a sufficient level for MR analysis (36, 37). Based on the merged dataset of exposure-outcome, harmonization of effect alleles and subsequent analyses were conducted. Detailed information regarding IVs is presented in Supplementary Tables 1–6.

Two-sample Mendelian randomization

Primary MR analysis was performed using the inverse-variance weighted (IVW) model, combining Wald estimates of causality for each IV with the assumption of invalid genetic instruments (e.g., a balanced pleiotropy) (38, 39). MR-Egger regression analysis and weighted-median estimator were used to examine any violation of MR assumptions caused by directional pleiotropy (40, 41). The MR-Egger intercept estimates the effect of pleiotropy across genetic variants and provides a relatively robust estimate with the independence of IV validity and an adjusted result via the regression slope (38, 40). A consistent valid estimate could be inferred by a weighted-median estimator if over 50% of instrumental variables were valid (40, 41). The weighted mode-based method infers robust overall causal estimates on the condition that individual estimates were mostly obtained from valid IVs (42). MR-Robust Adjusted Profile Score (MR-PAWPS) was used to derive a more accurate assessment of causal association with ideal independence of IVs (43).

In addition, MR pleiotropy residual sum and outlier (MR-PRESSO) was used to detect and correct horizontal pleiotropy by the removal of outliers with $p < 0.05$ and to give a corrected causal effect (44). Cochran’s Q-statistic was used to assess heterogeneity, and a random-effect model was used for subsequent analyses with $p < 0.05$ as a level of significant heterogeneity (45). In MR-PRESSO analysis, heterogeneity and pleiotropy in causal effect estimates were reduced by removing outliers and reassessing causal estimates. If heterogeneity was still significant after removing outliers, all SNPs with a $p$-value $< 1$ in the MR-PRESSO outlier test were removed. The MR analysis was re-performed with results from the random-effect IVW model being adopted. The number of distributions in the MR-PRESSO analysis was set to 1,000. Additional sensitivity analyses were performed by the exclusion of IVs one at a time (46). Other statistical tools were used to complement IVW and produced wider confidence intervals (CIs) (47). Therefore, IVW results were prioritized, and the MR-Egger was adopted for significant pleiotropy and the MR-PRESSO to detect final outliers. The flow chart of analytical methods used in this MR analysis is shown in Supplementary Figure 1.

In additional analyses, to investigate the direct effects of PUFAs on allergic diseases, MVMR analysis was also performed as an extension of univariable MR allowing the joint detection of causal effects of multiple risk factors (26, 48). Genetic associations between SNPs and age, average total household income, body mass index (BMI), smoking, and alcohol were obtained from a recent GWAS using a United Kingdom Biobank sample of 2,336,260 to 1,358,591 individuals of European
Mendelian randomization key hypothesis diagram. SNPs associated with PUFAs levels/ratios were used as the genetic instruments for investigating the causal effect of PUFA on allergic diseases. Line with arrows indicates that the genetic instruments (SNPs) are associated with the exposure and can only affect the outcome via the exposure. Dashed lines indicate that the genetic instruments (SNPs) are independent of confounders between the results.

Descent. MVMR takes into account the relationships among PUFAs, age, income, BMI, smoking, and alcohol drinking, and the fact that the SNPs selected in the MR analyses are often associated with several phenotypes. Therefore, MVMR was used to evaluate the direct effects of PUFAs independent of the effects of age, income, BMI, smoking, and alcohol assumptions on allergic diseases. The clumping window of $r^2 = 0.001$ and $kb = 10,000$ was also used to reduce the effect of strong LD in all
mediators. The combination of all GWAS-significant SNPs with a P-value less than $5 \times 10^{-8}$ were extracted from each exposure and were clump for avoiding LD under a window of $r^2 = 0.001$ and $kb = 10,000$. Selected IVs were further analyzed in the multivariable IVW and MR-Egger models, and a $P$-value < 0.05 was considered independently significant in the MVMR analysis. It should be noted that both IVW and MR-Egger methods could reveal heterogeneity in the analysis, and the results of MR-Egger would be applied when there was pleiotropy detected (26, 49).

**Statistical analysis**

Odds ratios and 95% CIs were used to express the impact on allergic disease risk caused by a corresponding unit change in absolute levels of the circulating omega-3, omega-6 and DHA and the ratio omega-6:3. According to the rules of Bonferroni correction for reduction of false positives by multiple tests, a two-sided $p$-value < 0.0083 was considered statistically significant but $p$-values $\geq$ 0.0083 and < 0.05 were only suggestive of statistical significance. MR analyses were performed using the “TwoSampleMR.” package (version 0.5.6) and Mendelian Randomization (50) (version 0.5.0) packages in R software (version 4.1.2), R Foundation for Statistical Computing, Vienna, Austria. All study results are reported according to STROBE-MR (Strengthening the Reporting of Observational Studies in Epidemiology—Mendelian Randomization) guidelines (51).

**Results**

Data regarding SNPs relating to omega-3, omega-6, DHA, LA, EPA, and omega-6:3 exposure are given in Supplementary Tables 1–6. F-statistics for all selected IVs are almost >10, indicating no weak IVs. Details of sensitivity analysis and outliers are shown in Table 1.

**Causal effects of omega-3/omega-6 on allergic diseases**

The association of omega-3 with AD risk showed no evidence of directional pleiotropy but significant heterogeneity, according to Cochran’s Q test ($Q = 79.029; p = 0.002$), but the removal of 3 outliers abolished heterogeneity. The genetically determined per unit increase in circulating omega-3 was associated with decreased risk of AD (outlier-corrected: OR: 0.863; 95% CI: 0.785 to 0.949; $p = 3.86E-03$).

No directional pleiotropy or heterogeneity was found for the association of circulating omega-3 on AC, AR or AU. A genetically determined increase in plasma omega-3 levels produced a trend with suggestive significance for decreased risk of AC (IVW-fixed: OR:0.720; 95% CI: 0.547 to 0.947; $p = 1.87E-02$) and AU (IVW-fixed: OR:0.821; 95% CI: 0.684 to 0.985; $p = 3.42E-02$), but no association was found between omega-3 and AR. Pleiotropy, assessed by MR-Egger regression (intercept = −0.014; $p = 0.005$), and heterogeneity ($Q = 127.849; p = 2.08E-09$) were analyzed for the relationship between circulating omega-3 and asthma, but after removal of six outliers, there was still no significant association (Figure 2).

No directional pleiotropy or significant heterogeneity was found for the analysis of circulating omega-6 levels and atopic diseases. A suggestively significant association emerged between omega-6 level and AC (IVW-fixed: OR:0.655; 95% CI: 0.445 to 0.964; $p = 3.18E-02$), but no relationship with other allergic diseases was found (Figure 3).

**Causal effects of docosahexaenoic acid, eicosapentaenoic acid, and linoleic acid on allergic diseases**

The association between DHA and AD showed heterogeneity, detected by Cochran’s Q test ($Q = 65.374; p = 0.009$), but no directional pleiotropy. The removal of 4 outliers abolished heterogeneity, allowing the adoption of a fixed-effect model. No genetic association was found between circulating DHA and AD. No heterogeneity or directional pleiotropy emerged from the analyses of DHA association with AC, AR or AU. A suggestively significant association was only revealed between the DHA level and decreased risk of AC (IVW-fixed: OR:0.671; 95% CI: 0.490 to 0.918; $p = 1.25E-02$). Pleiotropy, by MR-Egger regression (intercept = −0.013; $p = 0.004$), and heterogeneity ($Q = 70.079; p = 0.003$) were assessed in the analysis of DHA and asthma but after removal of four outliers (rs2394976, rs273912, rs4860987, rs77960347), no significant association was found (Figure 4). There was no significant association of LA and EPA with allergic diseases (Supplementary Figures 2, 3).

**Causal effects of the ratio of omega-6 to omega-3 on allergic diseases**

No heterogeneity or directional pleiotropy was found for the analyses of omega-6:3 on allergic diseases except for asthma and AU. Using the fixed-effect IVW model, circulating omega-6:3 was found to be significantly associated with an increased risk of AD (IVW-fixed OR:1.171; 95% CI: 1.045 to 1.312; $p = 6.46E-03$) and a suggestively significant association with increased risk of AC (IVW: OR:1.341; 95% CI: 1.032 to 1.743; $p = 2.83E-02$) was also found. There was no impact on AR. Significant heterogeneity and pleiotropy were detected respectively by Cochran’s Q test ($Q = 119.740; p = 1.76E-11$) and MR-Egger regression (intercept = 0.014; $p = 0.036$) for analysis.
| Exposure | Outcome | nIVs | Heterogeneity test | MR-Egger pleiotropy test | MR-PRESSO global test | MR-PRESSO distorted outlier test | F statistics |
|----------|---------|------|---------------------|-------------------------|----------------------|-----------------------------|-------------|
|          |         |      | Intercept (P-value) | adjusted Intercept (P-value) | RSSobs (P-value) | adjusted RSSobs (P-value) | Outlying SNPs | Heterogeneous SNPs |
| Omega-3  | AD      | 46   | 0.0026 (0.793)     | 0.0067 (0.2817)          | 83.3102 (0.010)     | 54.0308 (0.268)            | rs11242109   | rs144018203, rs3129962 |
|          | AC      | 48   | 0.0135 (0.4209)    | NA                      | 55.6056 (0.280)     | NA                          | None         | None |
|          | Asthma  | 42   | -0.0135 (0.0055)   | -0.0077 (0.0745)         | 146.0187 (<0.001)  | 43.4303 (0.478)            | None         | None |
|          | AR      | 48   | -0.0118 (0.0367)   | NA                      | 62.7635 (0.156)     | NA                          | None         | None |
|          | AU      | 48   | -0.0216 (0.0528)   | NA                      | 51.9311 (0.446)     | NA                          | None         | None |
| Omega-6  | AD      | 50   | 0.0128 (0.1055)    | NA                      | 55.0880 (0.309)     | NA                          | None         | None |
|          | AC      | 50   | 0.0433 (0.0521)    | NA                      | 54.6934 (0.334)     | NA                          | None         | None |
| Asthma   | 50      | 50   | 0.0015 (0.7368)    | NA                      | 58.3611 (0.216)     | NA                          | None         | None |
|          | AR      | 50   | -0.0001 (0.9904)   | NA                      | 59.4571 (0.196)     | NA                          | None         | None |
|          | AU      | 50   | -0.0122 (0.4298)   | NA                      | 41.1063 (0.818)     | NA                          | None         | None |
| RO63     | AD      | 35   | 0.0038(0.6241)     | NA                      | 55.3831 (0.060)     | NA                          | None         | None |
|          | AC      | 35   | 0.0140 (0.4342)    | NA                      | 34.6796 (0.394)     | NA                          | None         | None |
| Asthma   | 29      | 29   | 0.0315 (0.0361)    | -0.0012 (0.8455)        | 138.0924 (0.001)    | 32.6248 (0.347)            | None         | None |
|          | AR      | 35   | 0.0071 (0.3079)    | NA                      | 48.4527 (0.161)     | NA                          | None         | None |
|          | AU      | 35   | 0.0288 (0.0311)    | NA                      | 44.9988 (0.287)     | NA                          | None         | None |
| DHA      | AD      | 39   | 0.0095 (0.2291)    | 0.0006 (0.9525)         | 74.2713 (0.032)     | 42.9112 (0.333)            | None         | None |
|          | AC      | 42   | -0.0138 (0.4531)   | NA                      | 44.5644 (0.451)     | NA                          | None         | None |
| Asthma   | 37      | 35   | -0.0125 (0.0045)   | -0.0043 (0.4359)        | 90.4094 (0.019)     | 36.4349 (0.557)            | None         | None |

(Continued)
| Exposure | Outcome | nIVs | Heterogeneity test | MR-Egger pleiotropy test | MR-PRESSO global test | MR-PRESSO distorted outlier test |
|----------|---------|------|---------------------|--------------------------|-----------------------|---------------------------------|
|          |         |      | Q (P-value)         | adjusted Q (P-value)     | Intercept (P-value)   | adjusted Intercept (P-value)   |
|          |         |      |                     |                         |                      |                                 |
| AR       | 42      |      | 49.16 (0.1789)      | NA                      | -0.0099 (0.1289)     | NA                              |
| AU       | 42      |      | 46.89 (0.2436)      | NA                      | -0.0113 (0.4028)     | NA                              |
| LA       | 40      |      | 58.9174 (0.0431)    | 33.2374 (0.7295)        | 0.0138 (0.1832)      | 0.0168 (0.0626)                 | 62.5178 (0.0410) |
| AC       | 43      |      | 48.5985 (0.2244)    | NA                      | 0.0402 (0.1340)      | NA                              |
| Asthma   | 40      |      | 63.7698 (0.0167)    | 38.0106 (0.5149)        | 0.0017 (0.7751)      | -0.0026 (0.6079)                |
| AR       | 43      |      | 49.1533 (0.2084)    | NA                      | -0.0011 (0.9023)     | NA                              |
| AU       | 43      |      | 43.8677 (0.3923)    | NA                      | 0.0000 (0.9982)      | NA                              |
| EPA      | 7       |      | 11.1523 (0.0838)    | NA                      | 0.0866 (0.0319)      | NA                              |
| AC       | 7       |      | 3.7916 (0.7048)     | NA                      | 0.0525 (0.5606)      | NA                              |
| Asthma   | 7       |      | 9.8296 (0.1320)     | NA                      | -0.0211 (0.3652)     | NA                              |
| AR       | 7       |      | 5.1788 (0.5211)     | NA                      | 0.0149 (0.6195)      | NA                              |
| AU       | 7       |      | 4.1837 (0.6518)     | NA                      | 0.0592 (0.3644)      | NA                              |

As the Supplementary Figure 1 showed, for the process of adjustment, we firstly did a raw MR analysis and got an uncorrected causal evaluation. Then, MR-PRESSO global and Outliers test was performed to find unstable SNPs, and an adjusted MR analysis was performed again after removing all unstable SNPs, and the heterogeneity, pleiotropy and causal effect values were re-evaluated. MR: Mendelian randomization analysis; nIVs: Number of instrumental variables; NA: Not applicable; AD: atopic dermatitis; AC: Atopic conjunctivitis; AR: Allergic rhinitis; AU: Allergic urticaria; Omega-3: Omega-3 fatty acids; Omega-6: Omega-6 fatty acids; DHA: Docosahexaenoic acid.
FIGURE 2
The forest plot of univariable Mendelian randomization analyses exploring associations between omega-3 fatty acids and risk of allergic diseases using different Mendelian randomization statistical models OR: odds ratio; CIs: confidence intervals.
FIGURE 3
The forest plot of univariable Mendelian randomization analyses exploring associations between omega-6 fatty acids and risk of allergic diseases using different Mendelian randomization statistical models. OR: odds ratio; CIs: confidence intervals.
FIGURE 4
The forest plot of univariable Mendelian randomization analyses exploring associations between docosahexaenoic acid and allergic diseases risk using different Mendelian randomization statistical models. OR: odds ratio; CIs: confidence intervals.
of omega-6:3 and asthma. However, after the removal of six outliers, no significant association remained between omega-6:3 and asthma. Significant pleiotropy was detected by MR-Egger regression (intercept = 0.029; p = 0.031) for analysis of omega-6:3 and AU but the MR-PRESSO global test reported no evident pleiotropy (RSSobs = 44.398; p = 0.287). Therefore, the negative association between omega-6:3 with AU (MR-Egger: OR: 0.967; 95% CI: 0.753 to 1.243; p = 7.96E-01) should be interpreted with caution (Figure 5).

A forest plot of the causal estimates of PUFAs on allergic diseases is presented in Figures 2–5. Overall, the consistency of effect sizes across different methods indicates that confidence may be put in the results of each analysis. The corresponding scatter plots for the MR analysis are shown in Supplementary Figures 4–9.

The leave-one-out stability tests conducted by excluding a single SNP at a time are detailed in the Supplementary Figures 10–15. Risk estimates of genetically predicted omega-6 levels and omega-6:3 ratios for allergic diseases did not change substantially after excluding one SNP at a time, indicating that it was unlikely that potential driving SNPs were causing bias to the causal association. However, the removal of rs174564 from the two analyses of omega-3 and DHA levels on risk of AR, caused a distinct change in risk estimates, indicating that this instrumental variable severely affected the outcome variable. Therefore, these particular results should be interpreted with caution.

Multivariable MR analyses

We estimated the independent effects of circulating PUFAs on allergic diseases using multivariable MR conditioned on age, income, BMI, alcohol and smoking (Figure 6) and observed a directly protective effect of omega-3 level on AD (IVW ORMVMR: 0.841; 95% CI: 0.752 to 0.940; p = 2.00E-03) and AC (IVW ORMVMR: 0.646; 95% CI: 0.482 to 0.865; p = 3.00E-03). No significant was observed for omega-6 levels and allergic diseases after adjustment of age, income, BMI, alcohol, and smoking behaviors. Genetic risk of DHA was directly associated with decreased risk of AD (IVW ORMVMR: 0.851; 95% CI: 0.748 to 0.969; p = 1.50E-02). Genetic risk of circulating omega-6:3 was found to have a significant direct association with increased risk of AD (IVW ORMVMR: 1.192; 95% CI: 1.071 to 1.328; p = 1.00E-03) and AC (IVW ORMVMR: 1.384; 95% CI: 1.046 to 1.832; p = 2.30E-02). Similarly, there was no significant association of LA and EPA with allergic diseases according to the results of MVMR. Besides, though no significant genetic association was observed between PUFAs and asthma after adjustment of age, income, BMI, alcohol, and smoking behaviors, genetic risk of BMI was found to be associated with a higher risk of asthma. Detailed results of MVMR analyses were presented in Supplementary Tables 7-12.

Discussion

The current study explored the association between PUFAs and allergic disease risk using both univariable and multivariable two-sample MR. The IVs were used as proxies for PUFAs assessed both as absolute levels and as ratios to produce comparable results. In univariable MR results, Omega-3 levels were found to be likely genetic causal factors associated with decreased risk of some allergic diseases including AD, AC and AU. Genetic predisposition to high omega-6 and DHA levels was suggestively associated with reduced risk of AC. However, the genetic predisposition to high omega-6:3 showed a causal association with an increased risk of AD and AC, and this may constitute a susceptibility factor contributing to the pathogenesis of AD and AC. According to the results of MVMR, the independent protective effect of omega-3 and DHA on AD was identified in our study, as well as omega-3 for AC. Besides, omega-6:3 was independently associated with AD and AC. However, those results for asthma should be interpreted with caution as no specific GWAS data related to allergic asthma could be accessible and used in the present study.

Health benefits of PUFAs have been documented elsewhere and omega-3 (including DHA) have been associated with improvements in cardiovascular health, neurodevelopment and diabetes (52, 53) with omega-6 implicated in hair growth, lipid metabolism, and bone health (54–56). However, omega-3 and omega-6 compete for the same desaturation and elongation enzymes, and an increased ratio of omega-6 to omega-3 may reduce the benefits of omega-3 and increase the probability of inflammatory diseases (57). Inconsistencies have arisen from epidemiological studies, RCTs and meta-analyses into the effects of PUFAs intake during pregnancy (15, 58), biomarker levels (18, 59–64), maternal/individual early life PUFAs supplementation, and impacts on the risk of allergic diseases in the offspring or during individual later life (12, 14, 15, 65–67). For the association between PUFAs in plasma and allergic disease, there was evidence showing that higher levels of total omega-3 fatty acid, DHA and EPA in maternal and infant plasma were associated with a lower prevalence of IgE-associated disease (such as eczema) in a dose-dependent manner (68). Reduced concentration of serum omega-3 fatty acids was also identified to characterize women with extensive eczema (69). Previous observational studies mainly provided evidence for the effects of PUFAs composition of maternal and umbilical cord plasma on infants or early childhood allergic diseases, while the results in this MR study demonstrated a direct genetic association of circulating PUFAs with allergic skin diseases, especially for the protective effects of omega-3 fatty acid on AD and AC.

Multiple levels of research evidence should be considered when establishing causal effects but observational research under different conditions is susceptible to confounding factors reducing the accuracy of conclusions. Therefore, correlations
Figure 5

The forest plot of univariable Mendelian randomization analyses exploring associations between ratio of omega-6 fatty acids and omega-3 fatty acids to allergic diseases risk using different Mendelian randomization statistical models OR: odds ratio; CIs: confidence intervals.

| Model     | OR    | 95% CI          | P-value | Outcomes       |
|-----------|-------|-----------------|---------|----------------|
| IVW       | 1.173 | 1.043 to 1.3124 | 6.40E-03| Atopic dermatitis |
| MR-Egger  | 1.209 | 1.031 to 1.3942 | 2.45E-02|               |
| Weighted median | 1.196 | 1.077 to 1.3294 | 8.03E-04|               |
| Weighted mode | 1.208  | 1.076 to 1.3597 | 2.87E-03|               |
| MR-PRESSO | 1.178 | 0.969 to 1.4142 | 1.02E-01|               |
|          |       |                 |         | Atopic conjunctivitis |
| IVW       | 1.340 | 1.031 to 1.7428 | 2.83E-02|               |
| MR-Egger  | 1.237 | 0.983 to 1.5795 | 2.62E-01|               |
| Weighted median | 1.204  | 0.979 to 1.4749 | 1.30E-01|               |
| Weighted mode | 1.264  | 0.924 to 1.7291 | 1.52E-01|               |
| MR-PRESSO | 1.294 | 0.989 to 1.6933 | 6.00E-02|               |
|          |       |                 |         | Asthma          |
| IVW       | 0.952 | 0.862 to 1.0530 | 3.38E-01|               |
| MR-Egger  | 0.969 | 0.794 to 1.1817 | 7.59E-01|               |
| Weighted median | 0.982  | 0.860 to 1.1348 | 8.78E-01|               |
| Weighted mode | 0.960  | 0.823 to 1.1208 | 6.12E-01|               |
| MR-PRESSO | 0.949 | 0.861 to 1.0439 | 2.92E-01|               |
|          |       |                 |         | Allergic rhinitis |
| IVW       | 0.923 | 0.834 to 1.0234 | 1.25E-01|               |
| MR-Egger  | 0.881 | 0.770 to 1.0084 | 7.51E-02|               |
| Weighted median | 0.907  | 0.816 to 0.9918 | 4.11E-02|               |
| Weighted mode | 0.893  | 0.804 to 0.9923 | 4.38E-02|               |
| MR-PRESSO | 0.903 | 0.786 to 1.0392 | 1.56E-01|               |
|          |       |                 |         | Allergic urticaria |
| IVW       | 1.167 | 0.953 to 1.4274 | 1.30E-01|               |
| MR-Egger  | 0.967 | 0.725 to 1.2439 | 7.96E-01|               |
| Weighted median | 1.064  | 0.896 to 1.3221 | 4.72E-01|               |
| Weighted mode | 1.106  | 0.893 to 1.3742 | 3.69E-01|               |
| MR-PRESSO | 1.159 | 0.954 to 1.4018 | 1.36E-01|               |
|          |       |                 |         |                 |
| MR-PRESSO | 1.167 | 0.953 to 1.4274 | 1.39E-01|               |

Reported by observational studies cannot be equated with direct causal correlation. MR avoids the influence of confounding factors through genetic instrumental variables and accurate causal assessments may be made. Caution should also be exercised in comparing RCTs with MR effects since genetic susceptibility is considered lifelong, while the effects of dietary
supplementation in intervention experiments last only for the duration of the trial. Long-term exposure may be superior, given the long development period of allergic diseases.

The current study is the first MR analysis of PUFAs and allergic diseases and has several advantages. Firstly, compared with the inherent limitations of observational studies, MR studies are less likely to be affected by reverse causality and confounding. Secondly, extensive GWAS sample data, two separate sets of IVs and different methodologies were applied to causal association assessment to improve reliability. Moreover, the causal relationship was extended from single PUFA levels to include the ratio of omega-6 to omega-3. Several limitations must be acknowledged. Firstly, the present study is limited to individuals of European ancestry and may not be generalized to other races. Secondly, inconsistencies in pleiotropy detection and the occurrence of potential driving SNPs are difficult
to interpret and may cause bias. Thirdly, the GWAS effect size is based on circulatory PUFA concentration rather than membrane concentration, and membrane association may be more significant given the cell signaling of fatty acid receptors and immune responses (70, 71). Lastly, some more specific and targeted GWAS datasets, such as allergic asthma and eicosapentaenoic acid, were unavailable. However, as genetic instruments continue to improve, MR studies could shed further light on the significance of individual PUFA associations with the risk of specific allergic diseases.

Conclusion

In conclusion, through both univariable and multivariable MR analyses, our study demonstrated that higher PUFA concentrations (omega-3, DHA) and lower omega-6:3 ratios were associated with a lower risk of some allergic diseases (such as AD and AC). The strongest evidence concerned the protective effect of omega-3. This signifies the substantial clinical value of circulating PUFA levels and omega-6:3 on some allergic diseases and may assist with early diagnosis and enable more efficient targeting for prevention and therapy.

Data availability statement

The original contributions presented in this study are included in the article/Supplementary material, further inquiries can be directed to the corresponding author/s.

Author contributions

ZC and JW conceived the study, participated in its design and coordination, and critically revised the manuscript. YL and ZC searched the databases. ZC, QL, and YL reviewed the GWAS datasets and finished the data collection. ZC and YL finished the data analysis. YL drafted the manuscript, YL, JW, and ZC had full access to all the data collection, analysis, and interpretation. All authors read and approved the final manuscript.

Funding

This work was supported by the National Natural Sciences Foundation of China [No. 81472073], the National Key R&D Program of China [No. 2019YFA0112100], the Fundamental Research Funds for the Central Universities of Central South University [No. 2022ZZTS0824], and the Science Foundation of Hunan Province [No. 2019JJ40518]. The study funders/sponsors had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Acknowledgments

The authors would like to express their gratitude to EditSprings (https://www.editsprings.com/) for the expert linguistic services provided. The authors also would like to express their gratitude to the Special Project for Central Guidance of Local Science and Technology Development (2020YDDF00043); Changsha Clinical Research Center for Metabolic and Endocrine Diseases in the Elderly (KH2201058); Natural Science Foundation of Hunan Province, No. 2020JJ8012; Innovation Platform Project of Ningxia Clinical Research Center on Geriatric Diseases in 2020, No. 2020DPC05018; the 2021 Major RESEARCH and Development Program of Ningxia Hui Autonomous Region, No. 2021BEG01001; Ningxia Hui Autonomous Region Introduction Team (2020RXTD1X04); Education Department of Hunan Province, No. 18C0056; Project of Hunan Provincial Finance Department in 2017 (Hunan Finance Society refers to [2017] 61); and the Discipline Leader Project of “225” Project for Cultivating High-level Health Talents in Hunan Province. This manuscript is not under review with any other journal now and has not been published in any other journal previously.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fnut.2022.962787/full#supplementary-material
58. Venter C, Agostoni C, Arshad SH, Ben-Abdallah M, Du Toit G, Fleischer S, et al. Fatty acid supplementation on inflammatory markers and allergic diseases: a systematic review. *Pediatr Allergy Immunol*. (2021) 32:377–89. doi: 10.1111/pai.13654.

59. Standl M, Demmelmair H, Koletzko B, Heinrich J. Cord blood LC-PUFA composition and allergic diseases during the first 10 yr. Results from the LISAplus study. *Pediatr Allergy Immunol*. (2014) 25:344–50. doi: 10.1111/pai.12212

60. Barman M, Johansson S, Hesselman B, Wold AE, Sandberg AS, Sandin A. High levels of both n-3 and n-6 long-chain polyunsaturated fatty acids in cord serum phospholipids predict allergy development. *PLoS One*. (2013) 8:e67920. doi: 10.1371/journal.pone.0067920

61. Rucci E, den Dekker HT, de Jongste JC, Steenweg-de-Graaff J, Gaillard R, Pasmans SG, et al. Maternal fatty acid levels during pregnancy, childhood lung function and atopic diseases. The Generation R Study. *Clin Exp Allergy*. (2016) 46:461–71. doi: 10.1111/cea.12613

62. Notenboom ML, Mommers M, Jansen EH, Penders J, Thois C. Maternal fatty acid status in pregnancy and childhood atopic manifestations: KOALA birth cohort study. *Clin Exp Allergy*. (2011) 41:407–16. doi: 10.1111/j.1365-2222.2010.03672.x

63. Pike KC, Calder PC, Inskip HM, Robinson SM, Roberts GC, Cooper C, et al. Maternal plasma phospholipid fatty acids and atopy and wheeze in the offspring at age of 6 years. *Clin Dev Immunol*. (2012) 2012:474613. doi: 10.1155/2012/474613

64. Newson RB, Shaheen SO, Henderson AJ, Emmett PM, Sherriff A, Calder PC. Umbilical cord and maternal blood red cell fatty acids and early childhood wheezing and eczema. *Ann Allergy Asthma Immunol*. (2004) 93:531–7. doi: 10.1016/j.anai.2004.04.010

65. Zhang Y, Lin J, Zhou R, Zheng X, Dai J. Effect of omega-3 fatty acids supplementation during childhood in preventing allergic disease: a systematic review and meta-analysis. *J Asthma*. (2021) 58:523–36.

66. Best KP, Sullivan T, Palmer D, Gold M, Kennedy DJ, Martin J, et al. Prenatal fish oil supplementation and allergy: 6-year follow-up of a randomized controlled trial. *Pediatrics*. (2016) 137:e20154443. doi: 10.1542/peds.2015-4443

67. Vahdaninia M, Mackenzie H, Dean T, Helps S. n-3 LCPUFA supplementation during pregnancy and risk of allergic outcomes or sensitization in offspring: a systematic review and meta-analysis. *Ann Allergy Asthma Immunol*. (2012) 109:302.e–13.e. doi: 10.1016/j.anai.2011.12.008

68. Furuhøj C, Warstedt C, Fagerás M, Falth-Magnusson K, Larsson J, Fredriksson M, et al. Allergic disease in infants up to 2 years of age in relation to plasma omega-3 fatty acids and maternal fish oil supplementation in pregnancy and lactation. *Pediatr Allergy Immunol*. (2011) 22:505–14. doi: 10.1111/j.1399-3038.2010.01096.x

69. Johansson S, Wold AE, Sandberg AS. Low breast milk levels of long-chain n-3 fatty acids in allergic women, despite frequent fish intake. *Clin Exp Allergy*. (2011) 41:505–15. doi: 10.1111/j.1365-2222.2010.03678.x

70. Son SE, Koh JM, Im DS. Activation of free fatty acid receptor 4 (FFA4) ameliorates ovalbumin-induced allergic asthma by suppressing activation of dendritic and mast cells in mice. *Int J Mol Sci*. (2022) 23:5270. doi: 10.3390/ijms23095270

71. Patel D, Newell M, Goruk S, Richard C, Field CJ. Long chain polyunsaturated fatty acids docosahexaenoic acid and arachidonic acid supplementation in the suckling and the post-weaning diet influences the immune system development of T helper type-2 bias brown norway rat offspring. *Front Nutr*. (2021) 8:769293. doi: 10.3389/fnut.2021.769293